Back

Collaborator Presented New Data at ESMO 2019 Congress

Created on:
October 9, 2019

Dr. Tao Fu, from Gastrointestinal Surgery Department, Peking University Cancer Hospital, presented new data at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona,​​ Spain.

 

AccuraGen, as the main collaborator in Dr. Fu’s clinical study, provided whole-exome sequencing (WES) and ctDNA-NGS sequencing for this project. This new data supported AccureGen’s technology to predict neoadjuvant chemotherapy therapeutic efficacy by circulating tumor DNA in gastric cancer patients.

 

Poster:

Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer

 

Background: 

To verify the value of ctDNA and CTC as biomarkers for tumor response in the neoadjuvant chemotherapy (nCRT) treatment of locally advance gastric adenocarcinoma.

 

Methods: 

A total of 50 patients were enrolled. 20ml of plasma were collected at 3 points: before nCRT; after 2 cycles of nCRT; and after surgery. Firefly ctDNA-NGS assays were used to track ctDNA mutations previously. Using patient-specific mutation derived from exome sequencing of tumor tissues samples. Tumor response data by CT were also collected. CTCs in 7ml peripheral blood were also separated by a negative enrichment method and identified by FISH.

 

Results: 

A total of 10-20 somatic SNV or indel mutation were successfully identified for each patient. In comparison to basalline value of pre-chemotherapy blood, the ctDNA loading were decreased in post-chemotherapy specimens of 8 patients with TRG1 by histopathological grading or partial and complete response by CT scan.

All Journal Posts